Skip to content
eHealthTutorial — Research Peptide Reviews
Investigational • Not FDA-approved

Albumin-binding GHRH analogue research

CJC-1295 with DAC

The albumin-binding CJC-1295 analogue has been studied in small controlled trials measuring growth-hormone and IGF-I biomarkers in healthy adults. Biomarker responses do not establish clinical benefit or supplier-vial safety.

Open calculator Explore the research
Generic research visual — not a commercial product
Compound typeLong-acting GHRH analogue with affinity complex
Evidence baseSmall controlled human biomarker studies
Regulatory contextInvestigational / Not FDA-approved
Page purposeResearch and calculation

Compound calculator

CJC-1295 with DAC reconstitution calculator

Enter the values printed on your vial and the liquid volume you added to calculate concentration, liquid volume, and the corresponding mark on a U-100 syringe scale.

Selected peptide or compoundCJC-1295 with DAC
Enter the total amount printed on the vial.
mL
Enter the liquid volume added in milliliters.
You provide this amount; the calculator does not select or recommend it.
Scale reference only; confirm the markings on the physical syringe.

Your CJC-1295 with DAC calculation appears here

Enter the three required values to see the mathematical result.

This calculator performs arithmetic using values you enter. It does not select or recommend an amount, schedule, treatment, preparation method, or method of administration.

Research overview

What is CJC-1295 with DAC?

CJC-1295 with DAC is a modified growth-hormone-releasing-hormone analogue incorporating an albumin-binding drug-affinity complex. Its covalent association with endogenous albumin was investigated to extend exposure. The presence of DAC distinguishes it from the “no DAC” supplier term; studies of one form cannot be assigned to the other.

What has research examined?

Two randomized, placebo-controlled ascending-dose studies measured hormone and pharmacokinetic endpoints in healthy adults. The reported mean GH and IGF-I biomarkers rose after studied CJC-1295 exposure, and the reported estimated half-life was several days. A separate study examined growth-hormone pulsatility under sustained exposure. These are surrogate endocrine endpoints, not controlled evidence of a patient-centered benefit. FDA flags possible immunogenicity and peptide-related impurity characterization problems for compounded CJC-1295, limited clinical data, and reports of serious events such as increased heart rate and systemic vasodilatory reaction.

Important limitation

Small, short studies in healthy adults do not establish long-term safety or a disease-treatment effect. The investigated substance and formulation are not automatically equivalent to a seller’s vial. This page does not recommend hormone modulation, preparation, administration, or any amount.

Research references

Calculation boundary

The calculator performs concentration arithmetic only when a user enters a mass and liquid volume. It does not verify identity, formulation, purity, sterility, stability, compatibility, biological-unit equivalence, or whether reconstitution applies to a particular product. Do not convert IU or other biological units to mg without an authoritative, exact-product relationship.

For research purposes only. This page is educational and is not medical or veterinary advice or a recommendation to purchase, prepare, administer, or use any product.